Protein-based drugs encapsulation in biodegradable microparticles by co-axial electrospray
Multi-scale and/or multi-disciplinary approach to process-product innovation
Controlled Release of the Active Ingredient: Mechanisms, Devices & Analysis (T3-2P)
Keywords: co-axial, electrospray, encapsulation, drug delivery.
A co-axial electrospray process was developed to encapsulate protein-based drugs in biodegradable polymeric microparticles eliminating the key problem faced by other conventional methods of protein encapsulation – the primary emulsion being a major cause for protein denaturation and aggregation. Bovine serum albumin (BSA) and lysozyme were chosen as model protein drugs for this study. Scanning electron microscopy observation of the morphology of particles showed spherical microparticles of several microns could be achieved. The in vitro release profiles measured using Micro BCA assay suggested that sustained release of proteins could be attained for more than 30 days. The results of circular dichroism suggest that the secondary structure of released BSA can be retained. The bioactivity of released lysozyme was found to be more than 90%. Therefore, co-axial electrospray could be a very promising approach to encapsulate biomacromolecules such as proteins, enzymes, DNA plasmids or living cells inside microparticles for the controlled release drug delivery applications.
Presented Tuesday 18, 13:30 to 15:00, in session Controlled Release of the Active Ingredient: Mechanisms, Devices & Analysis (T3-2P).
